SGLT inhibitors for treating type 1 diabetes: NICE technology appraisals TA597 and TA622
Posted 12 Jun 2020
Dr David Millar-Jones summarises the key points for primary care relating to use of sodium–glucose cotransporter inhibitors in people with type 1 diabetes.
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page